NO20051138L - Nye farmasoytiske formuleringer av modafinil - Google Patents

Nye farmasoytiske formuleringer av modafinil

Info

Publication number
NO20051138L
NO20051138L NO20051138A NO20051138A NO20051138L NO 20051138 L NO20051138 L NO 20051138L NO 20051138 A NO20051138 A NO 20051138A NO 20051138 A NO20051138 A NO 20051138A NO 20051138 L NO20051138 L NO 20051138L
Authority
NO
Norway
Prior art keywords
modafinil
pharmaceutical formulations
new pharmaceutical
preparations
new
Prior art date
Application number
NO20051138A
Other languages
English (en)
Other versions
NO333725B1 (no
Inventor
Vincent Corvari
George Grandolfi
Alpa Parikh
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31991673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051138(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20051138L publication Critical patent/NO20051138L/no
Publication of NO333725B1 publication Critical patent/NO333725B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse er relatert til preparater av modafinil, omfattende preparater av modafinil og én eller flere fortynningsmidler, desintegreringsmidler, bindemidler og smøremidler og prosessene for deres tilvirkning.
NO20051138A 2002-09-13 2005-03-03 Preparat inneholdende modafinil NO333725B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/243,557 US7229644B2 (en) 2002-05-23 2002-09-13 Pharmaceutical formulations of modafinil
PCT/US2003/028528 WO2004024133A1 (en) 2002-09-13 2003-09-11 Novel pharmaceutical formulations of modafinil

Publications (2)

Publication Number Publication Date
NO20051138L true NO20051138L (no) 2005-03-21
NO333725B1 NO333725B1 (no) 2013-09-02

Family

ID=31991673

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051138A NO333725B1 (no) 2002-09-13 2005-03-03 Preparat inneholdende modafinil

Country Status (28)

Country Link
US (1) US7229644B2 (no)
EP (1) EP1556026B1 (no)
JP (2) JP5415662B2 (no)
KR (1) KR101125361B1 (no)
CN (2) CN100528150C (no)
AR (1) AR041242A1 (no)
AT (1) ATE434435T1 (no)
AU (1) AU2003270563B2 (no)
BR (1) BR0314515A (no)
CA (1) CA2498506C (no)
CY (1) CY1109465T1 (no)
DE (1) DE60328119D1 (no)
DK (1) DK1556026T3 (no)
EA (1) EA008506B1 (no)
ES (1) ES2325860T3 (no)
IL (1) IL167187A (no)
IS (1) IS2707B (no)
MX (1) MXPA05002832A (no)
MY (1) MY140081A (no)
NO (1) NO333725B1 (no)
NZ (1) NZ538940A (no)
PL (1) PL375831A1 (no)
PT (1) PT1556026E (no)
SI (1) SI1556026T1 (no)
TW (1) TWI316406B (no)
UA (1) UA88867C2 (no)
WO (1) WO2004024133A1 (no)
ZA (1) ZA200502792B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1787980T3 (da) 2000-07-27 2010-04-26 Teva Pharma Krystallint og rent modafinil og fremgangsmåde til atfremstille dette
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
AR046410A1 (es) * 2003-09-18 2005-12-07 Cephalon Inc Composiciones farmaceuticas para la liberacion modificada de modafinilo
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
US20060024370A1 (en) 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
EP3002005A1 (en) * 2014-09-30 2016-04-06 Molkerei Meggle Wasserburg GmbH & Co. Kg Direct compression excipient based on lactose, cellulose and starch
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
FR3117775B1 (fr) * 2020-12-18 2024-04-19 Commissariat Energie Atomique Produit pharmaceutique, son procédé de préparation et ses utilisations

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1570994A (en) 1923-11-20 1926-01-26 William A Cook Spring-forming die
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
GB9225492D0 (en) * 1992-12-05 1993-01-27 Glaxo Group Ltd Amine derivatives
US5843347A (en) 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2702968B1 (fr) 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
FR2706767B1 (no) 1993-06-22 1995-09-08 Lafon Labor
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
ATE254463T1 (de) * 1996-01-19 2003-12-15 Glaxo Group Ltd Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung
JPH09208468A (ja) * 1996-02-02 1997-08-12 Dainippon Pharmaceut Co Ltd ｐ−クロロ−Ｎ−（２−モルホリノエチル）ベンズアミドを含有する錠剤
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
JPH10179045A (ja) * 1996-12-25 1998-07-07 Osaka Kagaku Gokin Kk シート状可食性成形物
EA002806B1 (ru) * 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
HUP0104606A3 (en) * 1998-12-18 2003-01-28 Basf Ag A pharmaceutical mixture comprising a profen
ES2212667T3 (es) 1998-12-18 2004-07-16 Abbott Laboratories Formulacion de liberacion controlada con divalproex sodico.
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
JP3888064B2 (ja) * 2000-01-27 2007-02-28 田辺製薬株式会社 徐放性製剤およびその製法
US20010034373A1 (en) 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
DE60137069D1 (de) 2000-10-11 2009-01-29 Cephalon Inc Arzneizusammensetzungen enthaltend modafinilverbindungen
IL158959A (en) 2001-05-25 2010-06-30 Cephalon Inc Solid pharmaceutical formulations comprising modafinil
US7576133B2 (en) 2002-03-11 2009-08-18 Carl Henry Lawyer Methods and compositions for nasal administration of modafinil
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
MY137846A (en) 2002-07-08 2009-03-31 Ranbaxy Lab Ltd Processes for the preparation of oral dosage formulations of modafinil
AU2003247001A1 (en) 2002-07-25 2004-02-16 Ranbaxy Laboratories Limited Processes for the preparation of oral dosage formulations of modafinil
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil

Also Published As

Publication number Publication date
JP2014028833A (ja) 2014-02-13
ZA200502792B (en) 2006-03-29
BR0314515A (pt) 2005-08-09
CN100528150C (zh) 2009-08-19
CN1681485A (zh) 2005-10-12
IS2707B (is) 2011-01-15
MXPA05002832A (es) 2005-08-16
DK1556026T3 (da) 2009-08-24
CN101606915A (zh) 2009-12-23
ES2325860T3 (es) 2009-09-22
PL375831A1 (en) 2005-12-12
PT1556026E (pt) 2009-07-23
MY140081A (en) 2009-11-30
IL167187A (en) 2010-12-30
NZ538940A (en) 2008-07-31
EA200500486A1 (ru) 2005-08-25
AU2003270563B2 (en) 2008-11-13
IS7715A (is) 2005-02-24
ATE434435T1 (de) 2009-07-15
WO2004024133B1 (en) 2004-05-06
UA88867C2 (ru) 2009-12-10
TWI316406B (en) 2009-11-01
SI1556026T1 (sl) 2009-12-31
TW200500097A (en) 2005-01-01
AU2003270563A1 (en) 2004-04-30
WO2004024133A1 (en) 2004-03-25
KR20050053648A (ko) 2005-06-08
CA2498506A1 (en) 2004-03-25
JP2006501270A (ja) 2006-01-12
EP1556026A1 (en) 2005-07-27
EP1556026B1 (en) 2009-06-24
CN101606915B (zh) 2012-01-11
HK1078265A1 (en) 2006-03-10
AR041242A1 (es) 2005-05-11
JP5415662B2 (ja) 2014-02-12
US7229644B2 (en) 2007-06-12
NO333725B1 (no) 2013-09-02
DE60328119D1 (de) 2009-08-06
EA008506B1 (ru) 2007-06-29
KR101125361B1 (ko) 2012-03-27
CY1109465T1 (el) 2014-08-13
CA2498506C (en) 2012-01-03
US20030220403A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
NO20035211D0 (no) Faste farmasöytiske formuleringer omfattende modafinil
NO20051079L (no) Farmasoytiske formuleringer av modafinil
PH12021500030A1 (en) Il-2 conjugates and methods of use thereof
NO20070687L (no) Ny karbamylert EPO og fremgangsmate for deres fremstilling
NO20071078L (no) Antivirale forbindelser
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
MY151036A (en) Synthesis of (r)-n-methylnaltrexone
AP1770A (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their sythesis.
NO20054083L (no) Nye sammenkoblede triazoloner og deres anvendelse
NO20091976L (no) Nye forbindelser
SE0101675D0 (sv) Novel composition
CY1109465T1 (el) Νεες φαρμακευτικες φαρμακοτεχνικες μορφες μονταφινιλης
SE0301372D0 (sv) Novel compounds
NO20075997L (no) Methoder til furifysering av tigecyklin
TW200603798A (en) Disalt inhibitors of il-12 production
CO5611065A2 (es) Difluorometiltiazolilcarboxanilidas
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
NO20083214L (no) Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer
MX2024007966A (es) Anticuerpos anti-tslp novedosos.
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
NO20054762L (no) Polymorphs of aripiprazole
NO20044526L (no) Hemisterlinderivater og anvendelser derav
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
DK1622939T3 (da) Aktive varianter af det IL-18-bindende protein og medicinske anvendelser deraf

Legal Events

Date Code Title Description
LIS Published licence

Effective date: 20100506

MM1K Lapsed by not paying the annual fees